Pim-3 enhances melanoma cell migration and invasion by promoting STAT3 phosphorylation

References

• Uong A, Zon LI. Melanocytes in development and cancer. J Cell Physiol. 2010;222(1):38-41. doi:10.1002/jcp.21935.
   PubMed Web of Science ®Google Scholar
• Rinderknecht M, Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol. 2008;216(2):347-54. doi:10.1002/jcp.21494.
   PubMed Web of Science ®Google Scholar
• Diepenbruck M, Christofori G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr Opin Cell Biol. 2016;43:7-13. doi:10.1016/j.ceb.2016.06.002.
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166(1):21-45. doi:10.1016/j.cell.2016.06.028.
   PubMed Web of Science ®Google Scholar
• Li S, Lu J, Chen Y, Xiong N, Li L, Zhang J, Yang H, Wu C, Zeng H, Liu Y. MCP-1-induced ERK/GSK-3beta/Snail signaling facilitates the epithelial-mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells. Cell Mol Immunol. 2016;14(7):621-30. doi:10.1038/cmi.2015.106.
   PubMed Web of Science ®Google Scholar
• Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, Hutchinson P, Tse G, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013;24(4):466-80 doi:10.1016/j.ccr.2013.08.018.
   PubMed Web of Science ®Google Scholar
• Mukaida N, Wang YY, Li YY. Roles of Pim-3, a novel survival kinase, in tumorigenesis. Cancer Sci. 2011;102(8):1437-42. doi:10.1111/j.1349-7006.2011.01966.x.
   PubMed Web of Science ®Google Scholar
• Fujii C, Nakamoto Y, Lu P, Tsuneyama K, Popivanova BK, Kaneko S, Mukaida N. Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer. 2005;114(2):209-18. doi:10.1002/ijc.20719.
   PubMed Web of Science ®Google Scholar
• Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res. 2006;66(13):6741-47. doi:10.1158/0008-5472.CAN-05-4272.
   PubMed Web of Science ®Google Scholar
• Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, Mukaida N. Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci. 2007;98(3):321-28. doi:10.1111/j.1349-7006.2007.00390.x.
   PubMed Web of Science ®Google Scholar
• Guo Q, Lan P, Yu X, Han Q, Zhang J, Tian Z, Zhang C. Immunotherapy for hepatoma using a dual-function vector with both immunostimulatory and pim-3-silencing effects. Mol Cancer Ther. 2014;13(6):1503-13. doi:10.1158/1535-7163.MCT-13-0722.
   PubMed Web of Science ®Google Scholar
• Guo Q, Sui ZG, Xu W, Quan XH, Sun JL, Li X, Ji HY, Jing FB. Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells. Oncotarget. 2017;8(42):72652-65. doi:10.18632/oncotarget.20194
   PubMedGoogle Scholar
• Wang YY, Taniguchi T, Baba T, Li YY, Ishibashi H, Mukaida N. Identification of a phenanthrene derivative as a potent anticancer drug with Pim kinase inhibitory activity. Cancer Sci. 2012;103(1):107-15. doi:10.1111/j.1349-7006.2011.02117.x.
   PubMed Web of Science ®Google Scholar
• Xu D, Cobb MG, Gavilano L, Witherspoon SM, Williams D, White CD, Taverna P, Bednarski BK, Kim HJ, Baldwin AS, et al. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine. Cancer Biol Ther. 2013;14(6):492-501. doi:10.4161/cbt.24343.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Kwon SH, Yun JH, Jeong HS, Kim HR, Lee EH, Ye SK, Cho CH. STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression. Oncogene. 2017;36(39):5445-59. doi:10.1038/onc.2017.148.
   PubMed Web of Science ®Google Scholar
• Putz EM, Guillerey C, Kos K, Stannard K, Miles K, Delconte RB, Takeda K, Nicholson SE, Huntington ND, Smyth MJ. Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. Oncoimmunology. 2017;6(2):e1267892. doi:10.1080/2162402X.2016.1267892.
   PubMed Web of Science ®Google Scholar
• Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, Jetten AM, Khoury SJ, Fuhlbrigge RC, Kuchroo VK, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med. 2012;18(8):1248-53. doi:10.1038/nm.2856.
   PubMed Web of Science ®Google Scholar
• Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell. 2006;22(5):561-9. doi:10.1016/j.molcel.2006.05.012.
   PubMed Web of Science ®Google Scholar
• Ma Z, Zhang E, Yang D, Lu M. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol. 2015;12(3):273-82. doi:10.1038/cmi.2014.112.
   PubMed Web of Science ®Google Scholar
• Ren D, Liu F, Dong G, You M, Ji J, Huang Y, Hou Y, Fan H. Activation of TLR7 increases CCND3 expression via the downregulation of miR-15b in B cells of systemic lupus erythematosus. Cell Mol Immunol. 2016;13(6):764-75. doi:10.1038/cmi.2015.48.
   PubMed Web of Science ®Google Scholar
• Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7(6):415-28. doi:10.1038/nrc2131.
   PubMed Web of Science ®Google Scholar
• Li S, Lu J, Chen Y, Xiong N, Li L, Zhang J, Yang H, Wu CH, Zeng HJ, Liu YY. MCP-1-induced ERK/GSK-3β/Snail signaling facilitates the epithelial–mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells. Cell Mol Immunol. 2017;14:621-30. doi:10.1038/cmi.2015.106.
   PubMed Web of Science ®Google Scholar
• Yadav A, Kumar B, Datta J, Teknos TN, Kumar P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res. 2011;9(12):1658-67. doi:10.1158/1541-7786.MCR-11-0271.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Lim J, Yang Y, Lee MS, Lim JS. N-myc downstream-regulated gene 2 (NDRG2) suppresses the epithelial-mesenchymal transition (EMT) in breast cancer cells via STAT3/Snail signaling. Cancer Lett. 2014;354(1):33-42. doi:10.1016/j.canlet.2014.06.023.
   PubMed Web of Science ®Google Scholar
• Yin X, Zhang BH, Zheng SS, Gao DM, Qiu SJ, Wu WZ, Ren ZG. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling. J Hematol Oncol. 2015;8:23. doi:10.1186/s13045-015-0119-3.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang Y, Qian H, Zhang P, Huang C. Pim protein kinase-3 is regulated by TNF-alpha and promotes endothelial cell sprouting. Mol Cells. 2011;32(2):235–41. doi:10.1007/s10059-011-1026-z.
   PubMedGoogle Scholar
• Zhuang H, Zhao MY, Hei KW, Yang BC, Sun L, Du X, Li YM. Aberrant expression of pim-3 promotes proliferation and migration of ovarian cancer cells. Asian Pac J Cancer Prev. 2015;16(8):3325-31. doi:10.7314/APJCP.2015.16.8.3325.
   PubMedGoogle Scholar
• Santio NM, Eerola SK, Paatero I, Yli-Kauhaluoma J, Anizon F, Moreau P, Tuomela J, Harkonen P, Koskinen PJ. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts. PLoS One. 2015;10 (6):e0130340. doi:10.1371/journal.pone.0130340.
   PubMed Web of Science ®Google Scholar
• Chang M, Kanwar N, Feng E, Siu A, Liu X, Ma D, Jongstra J. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation. Mol Cancer Ther. 2010;9(9):2478-87. doi:10.1158/1535-7163.MCT-10-0321.
   PubMed Web of Science ®Google Scholar
• Park YK, Hong VS, Lee TY, Lee J, Choi JS, Park DS, Park GY, Jang BC. The novel anti-adipogenic effect and mechanisms of action of SGI-1776, a Pim-specific inhibitor, in 3T3-L1 adipocytes. Int J Mol Med. 2016;37(1):157-64. doi:10.3892/ijmm.2015.2415.
   PubMed Web of Science ®Google Scholar
• Liu B, Wang Z, Li HY, Zhang B, Ping B, Li YY. Pim-3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis. Oncol Rep. 2014;31(6):2625-34. doi:10.3892/or.2014.3158.
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798–809. doi:10.1038/nrc2734.
   PubMed Web of Science ®Google Scholar
• Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000;19(56):6613-26. doi:10.1038/sj.onc.1204086.
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7(6):454-65. doi:10.1038/nri2093.
   PubMed Web of Science ®Google Scholar
• Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117(12):3988-4002. doi:10.1172/JCI32533.
   PubMed Web of Science ®Google Scholar
• Yin W, Cheepala S, Roberts JN, Syson-Chan K, DiGiovanni J, Clifford JL. Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol Cancer. 2006;5:15. doi:10.1186/1476-4598-5-15.
   PubMed Web of Science ®Google Scholar
• Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005;24(36):5552-60. doi:10.1038/sj.onc.1208719.
   PubMed Web of Science ®Google Scholar
• Cao HH, Chu JH, Kwan H.Y, Su T, Yu H, Cheng CY, Fu XQ, Guo H, Li T, Tse AK, et al. Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma. Sci Rep. 2016;6:21731. doi:10.1038/srep21731.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Tokura Y. Epithelial-mesenchymal transition in the skin. J Dermatol Sci. 2011;61(1):7-13. doi:10.1016/j.jdermsci.2010.11.015.
   PubMed Web of Science ®Google Scholar
• Denecker G, Vandamme N, Akay O, Koludrovic D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M, Brochez L, et al. Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ. 2014;21(8):1250-61. doi:10.1038/cdd.2014.44.
   PubMed Web of Science ®Google Scholar
• Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R, Huang S. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006;66(6):3188-96. doi:10.1158/0008-5472.CAN-05-2674.
   PubMed Web of Science ®Google Scholar
• Xiao TS. Innate immunity and inflammation. Cell Mol Immunol. 2017;14:1-3. doi:10.1038/cmi.2016.45.
   PubMed Web of Science ®Google Scholar